Effect of dietary Lorenzo's oil and docosahexaenoic acid treatment for Zellweger syndrome

Congenital Anomalies

Volumn 48, Issue 4, 2008, Pages 180-182

  Arai, Yasuhiro ^a,b,c   Kitamura, Yohei ^f   Hayashi, Masaharu ^d   Oshida, Kyoichi ^e   Shimizu, Toshiaki ^b   Yamashiro, Yuichiro ^b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c Tokyo Metropolitan Coll   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^e Kemin Industries Inc   (United States)

^f Nutr Sci Inst Meiji Milk P   (Japan)

Author keywords

Docosahexaenoic acid; Lorenzo's oil; Very long chain fatty acids; Zellweger syndrome

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; GLYCYRRHIZIC ACID; LORENZO OIL; TAURINE; VERY LONG CHAIN FATTY ACID;

ARTICLE; AUTOPSY; CASE REPORT; CHILD DEATH; CHOLESTASIS; CLINICAL FEATURE; DIETARY INTAKE; DISSEMINATED INTRAVASCULAR CLOTTING; ERYTHROCYTE MEMBRANE; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; INFANT; INTESTINAL BLEEDING; LIVER DYSFUNCTION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; PRIORITY JOURNAL; SKIN BIOPSY; ZELLWEGER SYNDROME;

BRAIN CHEMISTRY; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; ERUCIC ACIDS; FATTY ACIDS; FEMALE; HUMANS; INFANT; LIVER; MALE; TRIOLEIN; ZELLWEGER SYNDROME;

EID: 55349110332     PISSN: 09143505     EISSN: 17414520     Source Type: Journal    
DOI: 10.1111/j.1741-4520.2008.00201.x     Document Type: Article

References (12)

1. Augbourg P, Adamsbaum C, Lavallard-Rousseau MC et al 1993) A two-year trial of oleic and eruic acids ('Lorenzo's oil') as treatment for adrenomyeloneuropathy. N Engl J Med 329 : 745 752.
2. Bourre JM, Daudu O, Baumann N et al 1976) Nervonic acid biosynthesis by erucyl-CoA elongation in normal and quaking mouse brain microsomes: Elongation of other unsaturated fatty acyl-CoAs (mono and poly-unsaturated). Biochim Biophys Acta 424 : 1 7.
3. Brown FR, Van Duyn MA, Moser AB et al 1982) Adrenoleukodystrophy: Effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med J 151 : 164 172.
4. Evrard P, Caviness VS, Prats-Vinas J et al 1978) The mechanism of arrest neuronal migration in the Zellweger malformation: An hypothesis based upon cytoarchitectonic analysis. Acta Neuropathol 41 : 109 117.
5. Innis SM (2003) Perinatal biochemical and physiology of long-chain polyunsaturated fatty acids. J Pediatr 143 : S1 S8.
6. Martinez M (1989) Polyunsaturated fatty acid changes suggesting a new enzymatic defect in Zellweger syndrome. Lipids 24 : 261 265.
7. Martinez M (1992) Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res 583 : 171 182.
8. Martinez M, Pineda M, Vidal R et al 1993) Docosahexaenoic acid-A new therapeutic approach to peroxisomal-disorder patients: Experience with two cases. Neurology 43 : 1389 1397.
9. Martinez M, Vazquez E (1998) MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology 51 : 26 32.
10. Martinez M, Vazquez E, Garcia-Silva MT et al 1999) Treatment of generalized peroxisomal disorders with docosahexaenoic acid ethyl ether. Rev Neurol 28 : 59 64.
11. Moser HW, Borel J (1995) Dietary management of X-linked adrenoleukodystrophy. Annu Rev Nutr 15 : 379 397.
12. Moser HW, Moser AB (1996) Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders. Lipids 31 : S141 S144.